International (Pediatric) Peritoneal Biobank
Launched by HEIDELBERG UNIVERSITY · Jul 2, 2013
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The International Pediatric Peritoneal Biobank trial is studying changes in the peritoneal membrane, which is important for children undergoing peritoneal dialysis (PD) due to kidney failure. This trial aims to collect tissue samples from children on PD to understand how their bodies react to the treatment and how these changes might affect their health. The researchers will gather these samples during routine medical procedures, like inserting a PD catheter or during surgeries, ensuring that the process is safe and does not significantly increase the risk of surgery.
To participate in this study, children and adults between the ages of 0 and 90 who are on PD or undergoing certain elective abdominal surgeries may be eligible. Participants will need to provide consent, and for younger patients, their parents or guardians will need to agree as well. By joining this trial, participants can help researchers learn more about the effects of PD on the body, which may lead to better treatment options in the future. This study is currently recruiting participants and is focused on understanding both the immediate and long-term impacts of PD on children’s health.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Age 0 to 90 years
- • CKD 5D, peritoneal dialysis and
- • Patients with normal renal function and elective abdominal surgery due to limited abdominal pathology (such as hernia repair, gallstones....)
- • Patients post PD and post Tx
- • Oral and written consent
- • Ability to consent of the adult patient and of the parents and legal guardian of patients not yet of legal age, respectively
- Exclusion Criteria:
- • Abdominal adhesions, malformation and inflammation beyond PD induced changes
- • Patients with disseminated tumour disease
- • Patients with critical heart failure and other medical conditions, where the additional procedure may confer an increased increase risk
- • Pregnancy
- • Preterm babies (below 37 weeks of gestational age)
- • Serum hemoglobin \< 10 g/dl in newborns and \< 8 g/dl in children and adults
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Missouri, United States
Birmingham, Alabama, United States
Stockholm, , Sweden
Essen, , Germany
Strasbourg, , France
Narberth, Pennsylvania, United States
Vienna, , Austria
Ghent, , Belgium
Prague, , Czechia
Lyon, , France
Heidelberg, Bw, Germany
Berlin, , Germany
Cologne, , Germany
Hamburg, , Germany
Marburg, , Germany
Budapest, , Hungary
Genova, , Italy
Milano, , Italy
Padova, , Italy
Vilnius, , Lithuania
Kuala Lumpur, , Malaysia
Krakow, , Poland
Barcelona, , Spain
Bern, , Switzerland
Adana, , Turkey
Istanbul, , Turkey
Patients applied
Trial Officials
Claus P Schmitt, MD
Principal Investigator
University of Heidelberg, Center for Pediatric and Adolescent Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials